Daily Morning Note – 30 November 2020

PHILLIP SUMMARY

Stocks in Asia are poised for gains as investors monitored progress on the path to a coronavirus vaccine on the final day of a record month for global equities. Oil is in focus. Stock futures traded higher late Friday in Japan and Hong Kong. On Sunday, the U.S. Surgeon General Jerome Adams said the federal government hopes to quickly review and approve requests from two big drugs makers for emergency approval of their Covid-19 vaccines. The pound ticked higher in early trading as Brexit talks continue.

BREAKING NEWS

Myanmar-focused Yoma Strategic Holdings’ full-year net loss has widened to US$60.5 million, from US$36.9 million a year ago. This comes amid a higher share of losses of joint ventures, an increase in the cost of sales, administrative expenses, as well as income tax expenses, showed results released by the mainboard-listed group on Saturday.

First Real Estate Investment Trust (First Reit) will restructure the master lease agreements of its 11 Indonesian hospital assets leased to former parent company Lippo Karawaci (LPKR). The trustee of First Reit on Saturday signed a memorandum of understanding (MOU) with LPKR, in which all the LPKR master lease agreements are extended to Dec 31, 2035, with an option for a further 15-year term by mutual agreement.

Mainboard-listed steel dealer BRC Asia’s full-year net profit fell 35.5 per cent to S$20.4 million, from S$31.6 million a year earlier, amid disruptions due to Covid-19. Revenue for the 12 months ended Sept 30, 2020 dropped 32.9 per cent to S$612.4 million, from S$913.3 million a year ago, on “substantially lower sales volume due to severe disruptions during and after the ‘circuit breaker’,” it said in a bourse filing on Saturday.

Food and beverage (F&B) play Jumbo Group is looking to acquire a 75 per cent interest in popular dumpling noodle stall Kok Kee Wanton Noodle for S$2.1 million in cash and shares. This will mark the group’s first inorganic expansion since it listed in 2015.

Thai Beverage Public Co (ThaiBev) said in a post-earnings conference call on Thursday evening that it does not expect a huge jump in sales in the months ahead as the pandemic’s impact lingers. Still, analysts remain upbeat about the company’s road to recovery.

Shares in Catalist-listed Biolidics rallied for a third consecutive day on Friday, advancing more than 20 per cent by the closing bell. This comes after the medtech firm announced it will distribute Covid-19 test kits in Indonesia, Singapore and the Philippines.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR

TECHNICAL REPORTS

NetEase Inc

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

NetEase Inc (US: NTES) corrective downside may soon be coming to an end based on the technical and wave analysis.

Sea Limited

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Sea Limited (US: SE) upside is still on play despite some minor correction since our report dated 28th October 2020. Recent technical indicate a return of the upside once more

>> Read more Technical reports

RESEARCH REPORTS

Thai Beverage PLC– A spirited performance

Recommendation: BUY (Maintained); TP S$0.86, Last close: S$0.75; Analyst Paul Chew

– 4Q20 revenue and earnings were within expectations, with FY20 numbers at 101%/99% of our forecasts. Revenue was up 2%, EBITDA up 31% YoY.

– 4Q20 spirit revenue rose 11% YoY on an 8.9% rise in volumes.

– 4Q20 EBITDA jumped 31% from higher sales and lower marketing costs.

– Maintain BUY. TP raised to S$0.86 from S$0.82 after we increase FY21e EPS (cents) by 4%. Our TP remains based on 18x earnings, its 5-year average. Operations have defied a challenging economic environment. Company benefitted from consumers’ trade-down to white spirits and aggressive cut to marketing spend. THBEV remains dominant in the spirit market and we expect a rebound in volumes in FY21e.

SG Bonds Weekly – Week 49

Credit Analyst: Timothy Ang

– Chinese real estate issuers remain active in the Asia primary debt market space pricing 5 deals totalling USD 920mm this week with average book coverage for Chinese real estate high yield new issues at 8.5x.

– Investor demand for high yield risk was very strong in the primary market this week with deals getting 7.8x covered on average.

– Singapore Airlines (SIA) has priced S$500 million worth of 3.5 per cent notes due 2030 under its S$10 billion multi-currency medium-term note programme.

– Singapore-based TML Holdings, a subsidiary of Indian carmaker Tata Motors, issued USD 300mm 3.5NC2.5 senior unsecured notes at 5.5%, after tightening 50bps from the initial price guidance.

>> Read more research reports

HK Reports – Read up on our Hong Kong reports here

RESEARCH VIDEOS

Webinar Of The Week

Market Outlook: SATS, StarHub, Civmec, Centurion, DBS, SREITs Monthly and SG Weekly

Date: 23 November 2020

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #26 – iX Biopharma Ltd; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com